Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04449510 · ClinicalTrials.gov registry record · NA
Short-Term Cardiovascular Effects of E-Cigarettes: Influence of E-Liquid pH
A NA study of Nicotine Dependence and Cardiovascular Risk Factor, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 2
- Study locations
NCT04449510: Completed NA study of Nicotine Dependence and Cardiovascular Risk Factor, sponsored by University of California, San Francisco.
NCT04449510 is a NA study of Nicotine Dependence and Cardiovascular Risk Factor that has completed, run by University of California, San Francisco. The registered enrollment target is 14 participants, below the 187-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04449510, a NA study of Nicotine Dependence and Cardiovascular Risk Factor, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will examine the short-term cardiovascular (CV) effects of e-liquid pH in a randomized, crossover clinical and behavioral pharmacology study of experienced adult e-cigarette users (N=21). The specific aim is to determine the impact of e-cigarette pH levels on nicotine pharmacology, systemic exposure to toxic volatile organic compounds (VOCs), and short-term cardiovascular effects.
Primary Outcome
Concentration of plasma nicotine (ng/ml) will be used to assess differences across the three e-liquid pH levels.
Conditions Studied
Interventions
- OTHER Electronic Cigarette
Study Locations (2)
California
- Zuckerberg San Francisco General Hospital - San Francisco
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-01-04 |
| Est. Completion | 2024-07-31 |
| Phase | NA |
What the finished NCT04449510 record still lists
NCT04449510 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 187-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Nicotine Dependence appearing as the primary indexed condition, and to 1 intervention - of which Electronic Cigarette is the first listed.
NCT04449510 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04449510 about?
NCT04449510 is a clinical study titled "Short-Term Cardiovascular Effects of E-Cigarettes: Influence of E-Liquid pH". This study will examine the short-term cardiovascular (CV) effects of e-liquid pH in a randomized, crossover clinical and behavioral pharmacology study of experienced adult e-cigarette users (N=21). The specific aim is to determine the impact of e-cigarette pH levels on nicotine pharmacology, system...
What is the current status of trial NCT04449510?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2021-01-04. Estimated completion is 2024-07-31.
What conditions does trial NCT04449510 study?
This clinical trial studies the following conditions: Nicotine Dependence, Cardiovascular Risk Factor.
What interventions are being tested in trial NCT04449510?
The interventions under investigation include: Electronic Cigarette (OTHER).
Who is sponsoring clinical trial NCT04449510?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04449510 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04449510's enrollment target sits among peer trials
14 63rd of 67 higher than 3 of 67 other Nicotine Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nicotine Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacokinetics and Pharmacodynamics of Nicotine With Use of Standardized Research Electronic Cigarette (SREC)
RECRUITING · NA
-
NeuroControl of Nicotine Dependence
RECRUITING · NA
-
Abuse Liability and Appeal of Oral Nicotine Products
RECRUITING · NA
-
Effects of E-cigs vs Pouches on Cigarette Smoking and Addiction
RECRUITING · NA
-
Young Adult Tobacco/Nicotine and Cannabis Co-use
RECRUITING · NA
-
Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy